Spotlight welcomes Curasight

Report this content

Today is the first day of trading in the research company Curasight, a Danish clinical phase II company based on more than a decade of research at Rigshospitalet and the University of Copenhagen.

Curasight has developed the concept for PET imaging based on the receptor, Upar, a known biomarker for cancer aggressiveness. The concept is the basis for Curasight's technology, uTRACE®., which can identify cancer and tumor aggressiveness, tumor invasion and the formation of cancer metastases. Through this image, Curasight's technology facilitates diagnosis and the choice of cancer treatment.

Curasight’s CEO Ulrich Krasilnikoff says "The capital that we are now provided with will finance the completion of a therapeutic preclinical study in brain cancer and a clinical phase III image study in brain cancer with the objective to obtain FDA approval and commercialize the uTRACE® platform”

"The life science sector is very important for our future and economy. Access to capital for Danish life science companies such as Curasight is vital, and it is a pleasure to see that Spotlight is part of facilitating this. I look forward to follow them on their journey.”
Katrine Hoff, Head of Danish Market.

Press contact
Jenny Sondal, CMO Spotlight
+46 70 7749303,


Spotlight is the marketplace where investors and growth companies meet. At Spotlight it is easier and safer for companies to be listed. We offer a overall solution that increase the visibility for our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in more than 170 growth companies from different businesses and countries, among those are Freetrailer, Bahnhof and Synthetic MR.




Documents & Links